L
Laura Vangeel
Researcher at Rega Institute for Medical Research
Publications - 38
Citations - 612
Laura Vangeel is an academic researcher from Rega Institute for Medical Research. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 7, co-authored 22 publications receiving 117 citations. Previous affiliations of Laura Vangeel include Katholieke Universiteit Leuven.
Papers
More filters
Journal ArticleDOI
The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model.
Rana Abdelnabi,Caroline S. Foo,Suzanne J.F. Kaptein,Xin Zhang,Thuc Nguyen Dan Do,Lana Langendries,Laura Vangeel,Judith Breuer,Juanita Pang,Rachel Williams,Valentijn Vergote,Elisabeth Heylen,Pieter Leyssen,Kai Dallmeier,Lotte Coelmont,Arnab K. Chatterjee,Raf Mols,Patrick Augustijns,Steven De Jonghe,Dirk Jochmans,Birgit Weynand,Johan Neyts,Johan Neyts +22 more
TL;DR: In this paper, the combined antiviral effect of Favipiravir and Molnupiravirus was evaluated in a SARS-CoV-2 Syrian hamster infection model.
Journal ArticleDOI
Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen
Maria Kuzikov,Elisa Costanzi,Jeanette Reinshagen,Francesca Esposito,Laura Vangeel,Markus Wolf,Bernhard Ellinger,Carsten Claussen,Gerd Geisslinger,Gerd Geisslinger,Angela Corona,Daniela Iaconis,Carmine Talarico,Candida Manelfi,Rolando Cannalire,Giulia Rossetti,Giulia Rossetti,Jonas Gossen,Simone Albani,Francesco Musiani,Katja Herzog,Yang Ye,Barbara Giabbai,Nicola Demitri,Dirk Jochmans,Steven De Jonghe,Jasper Rymenants,Vincenzo Summa,Enzo Tramontano,Andrea R. Beccari,Pieter Leyssen,Paola Storici,Johan Neyts,Philip Gribbon,Andrea Zaliani +34 more
TL;DR: In this article, compound repurposing is an important strategy for the identification of effective treatment options against SARS-CoV-2 infection and COVID-19 disease and 3CL-2 main protease (3CL-...
Journal ArticleDOI
The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir
Dirk Jochmans,Cheng Liu,Kim Donckers,Antitsa Dimitrova Stoycheva,Sandro Boland,Sarah K. Stevens,Chloe De Vita,Bert Vanmechelen,Piet Maes,Bettina Salome Trüeb,Nadine Ebert,Volker Thiel,Steven De Jonghe,Laura Vangeel,Dorothée Bardiot,Andreas Jekle,Lawrence M. Blatt,Leonid Beigelman,Julian A. Symons,Pierre Jean-Marie Bernard Raboisson,Patrick Chaltin,Arnaud Marchand,Johan Neyts,Jerome Deval,Koen Vandyck +24 more
TL;DR: This work describes for the first time a pathway that allows SARS-CoV-2 to develop resistance against Paxlovid in vitro, and identifies a combination of amino acid substitutions in 3CLpro that is associated with > 20x increase in EC50 values for ALG-097161, nirmatrelvir and PF-00835231.
Journal ArticleDOI
Transient Receptor Potential Channels and Calcium Signaling
Laura Vangeel,Thomas Voets +1 more
TL;DR: Important new insights are provided into the mechanisms whereby TRP channels permeate and sense Ca2+ and will be highly instrumental in the rational design of novel treatments for the multitude of TRP channel-related diseases.
Posted ContentDOI
Open Science Discovery of Oral Non-Covalent SARS-CoV-2 Main Protease Inhibitor Therapeutics
Hagit Achdout,A. Aimon,Elad Bar-David,Haim Barr,Amir Ben-Shmuel,Jim Bennett,Boby Ml,Borden B,Gregory R. Bowman,Juliane Brun,Bvnbs S,Mark Daniel Calmiano,Anna Carbery,Emma Cattermole,Chernyshenko E,John D. Chodera,Austin Clyde,Joseph E. Coffland,Galit Cohen,Jason C. Cole,Alessandro Contini,Cox L,Cvitkovic M,Alexandre Dias,Kim Donckers,Dotson Dl,Alice Douangamath,Shirly Duberstein,Dudgeon T,Louise Dunnett,Peter Eastman,Noam Erez,Eyermann Cj,Michael Fairhead,Fate G,D. Fearon,Oleg Fedorov,Matteo P. Ferla,R.S. Fernandes,Ferrins L,Richard Foster,Holly Foster,Ronen Gabizon,Adolfo García-Sastre,V.O. Gawriljuk,P. Gehrtz,Carina Gileadi,Charline Giroud,William G. Glass,Robert C. Glen,Itai Glinert,Andre S. Godoy,Marian V. Gorichko,T.J. Gorrie-Stone,Griffen Ej,Hart Sh,Jag Paul Heer,Henry M,Mark A. Hill,Horrell S,Matthew F. D. Hurley,Tomer Israely,Jajack A,Eric Jnoff,Dirk Jochmans,Tobias John,Steven De Jonghe,Anastassia L. Kantsadi,Peter W. Kenny,J. L. Kiappes,Koekemoer L,Kovar B,T. Krojer,Alpha A. Lee,Lefker Ba,Haim Levy,Nir London,Petra Lukacik,Hannah E. Bruce Macdonald,MacLean B,Tika R. Malla,Matviiuk T,William McCorkindale,McGovern Bl,Sharon Melamed,Oleg M. Michurin,Mikolajek H,Milne Bf,Morris A,Garrett M. Morris,Morwitzer Mj,Moustakas D,A.M. Nakamura,Jose Brandao Neto,Johan Neyts,Nguyen L,G.D. Noske,Oleinikovas,Glaucius Oliva,Gijs J. Overheul,David R. Owen,Psenak,Pai R,Pan J,Nir Paran,Benjamin Ian Perry,Pingle M,Pinjari J,Boaz Politi,A.J. Powell,Puni R,Victor L. Rangel,Rambabu N. Reddi,Reid Sp,Efrat Resnick,Ripka Eg,Matthew C. Robinson,Robinson Rp,Rodriguez-Guerra J,Rosales R,Rufa D,Christopher J. Schofield,Shafeev M,Shaikh A,Jiye Shi,Khriesto A. Shurrush,Sukrit Singh,Assa Sittner,R. Skyner,Adam Smalley,Smilova,Solmesky Lj,John Spencer,Claire Strain-Damerell,Swamy,Hadas Tamir,Tennant R,Thompson W,Andrew Thompson,Tomasio S,Anthony Tumber,Ioannis Vakonakis,van Rij Rp,Laura Vangeel,Finny S. Varghese,Vaschetto M,Einat B. Vitner,Voelz,Andrea Volkamer,von Delft F,von Delft A,Martin A. Walsh,Ward W,Charlie Weatherall,Shay Weiss,White Km,Wild Cf,Wittmann M,Nicholas A. Wright,Yfat Yahalom-Ronen,Zaidmann D,Zidane H,Nicole Zitzmann +162 more
TL;DR: The COVID Moonshot as discussed by the authors was a fully open-science structure-enabled drug discovery campaign targeting the SARS-CoV-2 main protease, which leveraged crowdsourcing, high throughput structural biology, machine learning, and exascale molecular simulations.